Medesis Pharma Extends Collaboration in Biopharm Sector

March 27, 2014
Philip Ward

Philip Ward is ACT's European editor, phone +44 1244 538583, philipward1@btconnect.com

Applied Clinical Trials

Medesis Pharma has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies

Medesis Pharma, a biopharmaceutical company represented in France and Canada, has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies (Commissariat à l'énergie atomique et aux énergies alternatives, CEA) on the development of compounds designed to remove radioactive/toxic metal contaminants from the body.

Medesis Pharma is targeting the defense markets and the civil nuclear industry (especially governmental stocks of decorporation products for civil protection in the vicinity of nuclear power plants). At present, there are no appropriate marketed products to use on a broad population for decorporation of plutonium and cesium, and there is no treatment for the decorporation of uranium, according to the company.

"Here at Medesis Pharma, we are delighted to extend and formalize our collaboration with CEA - simply the best possible partner for many opportunities in this part of the pharmaceutical market," commented Pharma Medesis' CEO Jean-Claude Maurel.

Meanwhile, Eric Quémeneur (Program and Research Exploitation Director in the CEA's Life Sciences Department) welcomed the opportunity to jointly develop original compounds in under-explored therapeutic areas.

Related Content:

News